DEA SUMMONS HAVE BEEN SERVED
Summons have been served on DEA officials, the Attorney General and the Administrative Law Judge to appear in Rhode Island federal court on MMJ's complaint.
WASHINGTON, DC / ACCESSWIRE / August 2, 2024 / In recent social media posts, the Democratic National Committee (DNC) claimed that the Biden administration had "reclassified marijuana" and ended the "failed approach to marijuana," symbolized with green checkmark emojis.
However, Tim Moynahan, lawyer and chairman of MMJ BioPharma Cultivation, criticized these claims, emphasizing that actions are more significant than words. MMJ BioPharma Cultivation filed a lawsuit in April 2024 against the DEA for delaying the approval process for marijuana clinical research by withholding the necessary federal DEA registrations. The idea that the administration has ended the "failed approach to marijuana" is even more of a stretch considering that, even if cannabis is rescheduled, it would remain federally illegal, maintaining the status quo policy of prohibition.
The idea that the administration has ended the "failed approach to marijuana" is even more of a stretch considering that, even if cannabis is rescheduled, it would remain federally illegal, maintaining the status quo policy of prohibition.
Summons have been served on the DEA officials, the Attorney General, and the Administrative Law Judge to appear in federal court.
MMJ's Strategic Shift: Cannabis 3.0
Speaking at a Cannabis Forum, Duane Boise highlighted MMJ's strategic focus on pharmaceutical drug development and clinical trials, rather than relying on the uncertain path of federal legalization for recreational and medicinal marijuana businesses, MMJ's innovative approach is set to define the emerging "Cannabis 3.0" era.
FDA Approval for THC-CBD Drugs
MMJ BioPharma's triad of companies, in collaboration with a specialty Schedule I pharmaceutical soft gelatin manufacturing company, has successfully manufactured a THC-CBD medicine formulated from cannabis plant compounds. This novel pharmaceutical will undergo clinical trials to demonstrate its safety, efficacy, and treatment potential for multiple sclerosis (MS) and Huntington's disease (HD) patients. Upon FDA approval for clinical trials, MMJ will be the only company with a natural plant extract-based THC and CBD final dose form pill. This product is manufactured following the FDA's current Good Manufacturing Practices guidelines.
Dr. Elio Mariani, MMJ's CEO, noted, "MMJ International Holdings has diligently worked for years to develop the pill and compile the data mandated by the FDA for approval."
Supreme Court Ruling Challenges Chevron Deference and DEA Policies
The Supreme Court's recent decision to overturn the Chevron doctrine marks a significant shift in administrative law, reducing federal agencies' power to interpret ambiguous statutes and enhancing judicial oversight.
Understanding Chevron Deference
Established in 1984, the Chevron doctrine allowed courts to defer to agency interpretations of ambiguous statutes, provided the interpretation was reasonable. This doctrine granted agencies like the DEA substantial authority to define and enforce rules based on their interpretations of statutory ambiguities.
Impact of the Ruling on the DEA and MMJ BioPharma Cultivation
The Supreme Court's decision challenges this deference, impacting on-going cases like MMJ BioPharma Cultivation's legal battle against the DEA. With Chevron deference curtailed, the DEA will face increased legal challenges. MMJ BioPharma will argue that the DEA's restrictive interpretation of their own rules can be reviewed and overturned in federal court.
MMJ BioPharma's Unanswered Appeals to Rhode Island Senators
MMJ BioPharma sent letters to Senator Jack Reed and Senator Sheldon Whitehouse seeking intervention and support on the marijuana issue. However, there was no response or intervention from the two Rhode Island Senators, failing to address the critical delays and challenges faced by MMJ BioPharma in advancing marijuana pharmaceutical research.
The Biden-Harris administration's marijuana policy has been criticized by MMJ BioPharma Cultivation and others for its lack of effective action. MMJ continues to challenge the DEA's delays in granting research registrations in federal court. Meanwhile, the Supreme Court's recent decision to limit Chevron deference provides a new legal pathway for MMJ to contest DEA's uncompassionate policies toward manufacturing medicine for suffering patients. The lack of response from Senators Reed and Whitehouse further underscores the challenges and ambiguity presented to MMJ BioPharma in advancing their research and development efforts.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
media@mmjih.com
203-231-8583
SOURCE: MMJ BioPharma Cultivation
View the original press release on accesswire.com
